Medicxi is a life sciences-focused investment firm.
Business Model:
Revenue: $1M
Employees: 11-50
Address: 25 Great Pulteney Street
City: London
State: england
Zip: W1F 9LT
Country: GB
Medicxi is an international investment firm focused on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2017 | Palladio Biosciences | Series A | - |
7/2019 | Breakpoint Therapeutics | Venture Round | 33.6M |
1/2020 | Vaderis Therapeutics | Series A | 18.6M |
3/2016 | Gadeta | Series A | 7.9M |
4/2019 | Aura Biosciences | Series D | 40M |
9/2020 | Palladio Biosciences | Series B | 20M |
11/2017 | Critical Pressure | Series A | 13.2M |
9/2019 | Divide and Conquer | Series A | 12.4M |
10/2017 | Impact Biomedicines | Series A | 22M |
2/2019 | Inexia | Seed Round | - |
12/2018 | Morphogen-IX | Series B | 23.3M |
7/2021 | Rivus Pharmaceuticals | Series A | 35M |
10/2017 | Sydnexis | Venture Round | 5.5M |
7/2017 | Diasome Pharmaceuticals | Venture Round | 0 |
5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
2/2017 | ApcinteX | Series A | 17.5M |
3/2016 | Capella BioScience | Series A | 15.5M |
4/2018 | Synthorx | Series C | 63M |
10/2017 | Janpix | Series A | 17.7M |
10/2020 | Janpix | Series B | 10M |
2/2019 | Orexia | Seed Round | - |
12/2014 | Stealthyx Therapeutics | Seed Round | 3.1M |
6/2019 | Yukin Therapeutics | Venture Round | 3.7M |
10/2016 | Mavalon Therapeutics | Seed Round | 0 |
1/2020 | Alderaan Biotechnology | Series A | 20.6M |
2/2017 | SuperX | Series A | 11M |
6/2022 | MiroBio | Series B | 0 |
6/2018 | Vaxcyte | Series C | 85M |
8/2021 | Sydnexis | Series B | 0 |
11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
3/2020 | Vaxcyte | Series D | 0 |
5/2018 | Xenikos | Series B | 30M |
5/2017 | Z Factor | Series A | 9M |
9/2021 | Xenikos | Convertible Note | 47.3M |
8/2021 | Versanis Bio | Series A | 0 |
10/2016 | Kymo Therapeutics | Seed Round | 11M |
6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
3/2021 | Aura Biosciences | Venture Round | 0 |
6/2021 | Kurome Therapeutics | Series A | 0 |
9/2022 | Rivus Pharmaceuticals | Series B | 132M |
6/2022 | MiroBio | Series B | 0 |
9/2021 | Xenikos | Convertible Note | 0 |
8/2021 | Versanis Bio | Series A | 0 |
8/2021 | Sydnexis | Series B | 0 |
7/2021 | Rivus Pharmaceuticals | Series A | 0 |
6/2021 | Kurome Therapeutics | Series A | 0 |
3/2021 | Aura Biosciences | Venture Round | 0 |
10/2020 | Janpix | Series B | 0 |
9/2020 | Palladio Biosciences | Series B | 0 |
6/2020 | Checkmate Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|